SI1128819T1 - New controlled release bead, a method of producing the same and multiple unit formulation comprising it - Google Patents

New controlled release bead, a method of producing the same and multiple unit formulation comprising it

Info

Publication number
SI1128819T1
SI1128819T1 SI9930411T SI9930411T SI1128819T1 SI 1128819 T1 SI1128819 T1 SI 1128819T1 SI 9930411 T SI9930411 T SI 9930411T SI 9930411 T SI9930411 T SI 9930411T SI 1128819 T1 SI1128819 T1 SI 1128819T1
Authority
SI
Slovenia
Prior art keywords
producing
same
controlled release
multiple unit
unit formulation
Prior art date
Application number
SI9930411T
Other languages
English (en)
Slovenian (sl)
Inventor
Torkel Gren
Anders Ringberg
Martin Wikberg
Randy J. Wald
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1128819(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/SE1999/001463 external-priority patent/WO2000012069A1/en
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of SI1128819T1 publication Critical patent/SI1128819T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI9930411T 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it SI1128819T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9803871A SE9803871D0 (sv) 1998-11-11 1998-11-11 Therapeutic method and formulation
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
PCT/SE1999/002052 WO2000027364A1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it
EP99971702A EP1128819B1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it

Publications (1)

Publication Number Publication Date
SI1128819T1 true SI1128819T1 (en) 2003-12-31

Family

ID=20413266

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930411T SI1128819T1 (en) 1998-11-11 1999-11-11 New controlled release bead, a method of producing the same and multiple unit formulation comprising it

Country Status (40)

Country Link
US (1) US6911217B1 (xx)
EP (1) EP1128819B1 (xx)
JP (1) JP3616011B2 (xx)
KR (1) KR100467384B1 (xx)
CN (1) CN1169522C (xx)
AP (1) AP1323A (xx)
AR (1) AR027815A1 (xx)
AT (1) ATE247458T1 (xx)
AU (1) AU762410B2 (xx)
BG (1) BG65149B1 (xx)
BR (1) BRPI9915142B8 (xx)
CA (1) CA2350061C (xx)
CZ (1) CZ299582B6 (xx)
DE (1) DE69910604T2 (xx)
DK (1) DK1128819T3 (xx)
EA (1) EA005074B1 (xx)
EE (1) EE05232B1 (xx)
ES (1) ES2204193T3 (xx)
GE (1) GEP20022833B (xx)
HK (1) HK1040917B (xx)
HR (1) HRP20010333B1 (xx)
HU (1) HU226582B1 (xx)
ID (1) ID30039A (xx)
IL (1) IL142809A0 (xx)
IS (1) IS2370B (xx)
MA (1) MA25325A1 (xx)
MY (1) MY122195A (xx)
NO (1) NO331399B1 (xx)
NZ (1) NZ511430A (xx)
OA (1) OA11673A (xx)
PL (1) PL195780B1 (xx)
PT (1) PT1128819E (xx)
RS (1) RS49891B (xx)
SE (1) SE9803871D0 (xx)
SI (1) SI1128819T1 (xx)
SK (1) SK284758B6 (xx)
TW (2) TWI222879B (xx)
UA (1) UA57165C2 (xx)
WO (1) WO2000027364A1 (xx)
ZA (1) ZA200103575B (xx)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0924983A4 (en) * 1996-07-19 1999-08-25 Gunnar Aberg S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
PT1227806E (pt) * 1999-11-11 2005-10-31 Pfizer Health Ab Formulacao farmaceutica contendo tolterodina e sua utilizacao
MXPA05002302A (es) * 2002-08-28 2005-06-08 Pharmacia Corp Composicion liquida oral de tolterodina.
US8168170B2 (en) 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
MXPA05007767A (es) * 2003-01-22 2006-01-31 Pfizer Health Ab Dosis reducida de tolterodina y otros agentes antimuscarinicos para tratar trastornos urinarios.
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
EP1680110B1 (en) 2003-11-04 2011-01-05 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
EP1680100A4 (en) 2003-11-04 2012-08-08 Supernus Pharmaceuticals Inc QUATERNARY AMMONIUM COMPOUNDS CONTAINING BIOAVAILABILITY ACTIVATORS
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2006074479A1 (en) * 2005-01-10 2006-07-13 Teva Pharmaceutical Industries, Ltd. Process for preparing tolterodine tartrate
AR052472A1 (es) 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007083309A2 (en) * 2006-01-18 2007-07-26 Intec Pharma Ltd. Method and apparatus for forming delivery devices for oral intake of an agent
CA2882048C (en) 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
KR100714058B1 (ko) * 2006-02-06 2007-05-02 한국유나이티드제약 주식회사 톨테로딘 엘-주석산염의 서방형 경구투여 조성물 및 이의 제조 방법
US20070202172A1 (en) * 2006-02-24 2007-08-30 Tomer Gold Metoprolol succinate E.R. tablets and methods for their preparation
KR20080106358A (ko) * 2006-03-21 2008-12-04 테바 파마슈티컬 인더스트리즈 리미티드 톨터로딘의 제어 방출 제형
EP1839649A1 (en) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Coated formulations for tolterodine
US9561188B2 (en) * 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
WO2007122015A1 (en) * 2006-04-21 2007-11-01 Synthon B.V. Tolterodine beads
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2026766A1 (en) 2006-05-17 2009-02-25 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
DK3357496T3 (da) 2006-06-21 2020-05-11 Opko Ireland Global Holdings Ltd Terapi ved brug af vitamin d-repletteringsmiddel og vitamin d-hormonsubstitutionsmiddel
JP2008007458A (ja) * 2006-06-29 2008-01-17 Freunt Ind Co Ltd レイヤリング用核粒子とその製造方法
EA018036B1 (ru) 2006-11-27 2013-05-30 Х. Лундбекк А/С Гетероариламидные производные
AU2008211600B8 (en) 2007-02-01 2014-02-13 Mars, Incorporated Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
KR101495578B1 (ko) 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
EP2148683A4 (en) 2007-04-25 2012-09-12 Proventiv Therapeutics Llc METHOD FOR THE SAFE AND EFFECTIVE TREATMENT AND PREVENTION OF SECONDARY HYPERPARATHYREOSIS IN CHRONIC KIDNEY DISEASE
ES2956794T3 (es) 2007-04-25 2023-12-28 Eirgen Pharma Ltd Liberación controlada de 25-hidroxivitamina D
US20090017111A1 (en) * 2007-07-03 2009-01-15 Van Den Heuvel Dennie J M Tolterodine bead
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
BRPI0815387B8 (pt) 2007-08-13 2021-05-25 Abuse Deterrent Pharmaceutical Llc composição farmacêutica, método para fazer uma composição farmacêutica e uso da composição farmacêutica
US20090192228A1 (en) * 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
CA2629099A1 (en) * 2008-04-01 2009-10-01 Pharmascience Inc. Novel oral controlled release pharmaceutical formulations
EP2281058B1 (en) 2008-04-02 2016-06-29 Opko Ireland Global Holdings, Ltd. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
US20090311317A1 (en) * 2008-05-14 2009-12-17 Capricorn Pharma Inc. Modified release tolterodine formulations
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CA2769760A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
WO2011061616A2 (en) 2009-11-23 2011-05-26 Micro Labs Limited Extended release compositions containing tolterodine and process for preparing the same
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
AU2011234637B2 (en) 2010-03-29 2013-08-29 Ferring B.V. A fast dissolving pharmaceutical composition
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
EP3636280A1 (en) 2010-03-29 2020-04-15 Opko Ireland Global Holdings, Ltd. Methods and compositions for reducing parathyroid levels
US8748433B2 (en) 2010-04-30 2014-06-10 Merck Sharp & Dohme Corp. β3 adrenergic receptor agonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
WO2012154770A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
GR1007628B (el) 2011-07-27 2012-06-29 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου
EP2755632A1 (en) 2011-09-16 2014-07-23 Ferring BV A fast dissolving pharmaceutical composition
WO2013047795A1 (ja) * 2011-09-30 2013-04-04 アステラス製薬株式会社 粒子状医薬組成物
EP3275466A1 (en) 2012-07-12 2018-01-31 Ferring B.V. Diclofenac formulations
KR20150083841A (ko) * 2012-09-20 2015-07-20 오에이치알 파마, 엘엘씨. 치료제의 서방을 위한 다층 생분해성 미세입자
TW201422254A (zh) * 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
US20150306170A1 (en) * 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
WO2014159051A1 (en) * 2013-03-13 2014-10-02 Advanced Bionutrition Corp. Stable bioactive substances and methods of making
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
AU2014246617A1 (en) 2013-12-23 2015-07-09 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CA2936741C (en) * 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US20190083628A1 (en) * 2016-02-23 2019-03-21 Nipro Corporation Pharmaceutical composition particles and orally disintegrating preparation including the same
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1144911B (it) * 1981-03-19 1986-10-29 Pharmatec Spa Composizione farmaceutica a rilascio controllato contenente ibuprofen
JPH07107450A (ja) 1993-10-08 1995-04-21 Hitachi Ltd 情報通信装置
JP3453186B2 (ja) 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
US5645858A (en) * 1994-10-06 1997-07-08 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
EP0924983A4 (en) 1996-07-19 1999-08-25 Gunnar Aberg S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS
US6312728B1 (en) * 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
HUP0105038A2 (en) 2002-06-29
JP2003517446A (ja) 2003-05-27
KR20010075695A (ko) 2001-08-09
IS5936A (is) 2001-05-09
DE69910604T2 (de) 2004-06-24
RS49891B (sr) 2008-08-07
HUP0105038A3 (en) 2006-07-28
EP1128819A1 (en) 2001-09-05
YU33101A (sh) 2003-10-31
CZ299582B6 (cs) 2008-09-10
GEP20022833B (en) 2002-11-25
HRP20010333A2 (en) 2003-04-30
HRP20010333B1 (en) 2004-10-31
US6911217B1 (en) 2005-06-28
PL195780B1 (pl) 2007-10-31
IL142809A0 (en) 2002-03-10
HU226582B1 (en) 2009-04-28
TWI222879B (en) 2004-11-01
EA200100538A1 (ru) 2001-10-22
MA25325A1 (fr) 2001-12-31
ES2204193T3 (es) 2004-04-16
HK1040917B (zh) 2005-05-27
CA2350061A1 (en) 2000-05-18
PL348612A1 (en) 2002-06-03
OA11673A (en) 2005-01-12
SE9803871D0 (sv) 1998-11-11
AU1436600A (en) 2000-05-29
BR9915142A (pt) 2001-08-07
ATE247458T1 (de) 2003-09-15
BG105582A (en) 2001-12-29
SK284758B6 (sk) 2005-11-03
NO20012314L (no) 2001-07-09
BG65149B1 (bg) 2007-04-30
AU762410B2 (en) 2003-06-26
CN1326339A (zh) 2001-12-12
CA2350061C (en) 2005-05-17
EP1128819B1 (en) 2003-08-20
JP3616011B2 (ja) 2005-02-02
KR100467384B1 (ko) 2005-01-24
NZ511430A (en) 2003-05-30
UA57165C2 (uk) 2003-06-16
BRPI9915142B1 (pt) 2015-08-25
AR027815A1 (es) 2003-04-16
ZA200103575B (en) 2002-05-03
NO20012314D0 (no) 2001-05-10
HK1040917A1 (en) 2002-06-28
BRPI9915142B8 (pt) 2021-05-25
EE200100254A (et) 2002-12-16
CN1169522C (zh) 2004-10-06
MY122195A (en) 2006-03-31
DK1128819T3 (da) 2003-12-01
EA005074B1 (ru) 2004-10-28
WO2000027364A1 (en) 2000-05-18
PT1128819E (pt) 2003-12-31
TWI267385B (en) 2006-12-01
SK6252001A3 (en) 2002-01-07
ID30039A (id) 2001-11-01
IS2370B (is) 2008-06-15
AP1323A (en) 2004-11-05
AP2001002166A0 (en) 2001-06-30
DE69910604D1 (de) 2003-09-25
NO331399B1 (no) 2011-12-19
CZ20011627A3 (cs) 2001-10-17
EE05232B1 (et) 2009-12-15

Similar Documents

Publication Publication Date Title
PL348612A1 (en) New controlled release bead, a method of producing the same and multiple unit formulation comprising it
AU1943699A (en) Patterned coated articles and methods for producing the same
HK1031382A1 (en) Spiroazabicyclic heterocyclic compounds, a method for producing the same and use thereof
HK1044338A1 (en) 5-Pyridyl-1, 3-azole compounds, process for producing the same and use thereof
HUP0003200A3 (en) Method for making a relatively soft product, and the product itself
HUP0101192A3 (en) Cycloalkene derivatives, process for producing the same, and use
AU5855498A (en) Monoolefinic c5-mononitriles, method for the production and the use thereof
AU3031899A (en) Nanoparticles, method for producing nanoparticles and use of the same
AU7809198A (en) Electoluminescent device and method for producing the same
AU5398298A (en) Neutral-tasting microcapsules, method for their manufacturing and their use
ZA973433B (en) A sertindole-containing preparation and a method for producing the same.
AU9423698A (en) Heating element and method for producing the same
AU5645598A (en) New benzoxazinedione derivatives, a method of producing them and the use thereof
AU2001288789A1 (en) Airbag and method for producing the same
AU6333199A (en) Webbing and method for producing the same
AU2002227966A1 (en) Coniosetin and derivatives thereof, method for producing the same and use thereof
IL138904A0 (en) Magnetic- abrasive powder, and method of producing the same
AU2796602A (en) Coniosetin and derivatives thereof, method for producing the same and use thereof
AU2002221904A1 (en) Ceiling and method for producing the same
AU3274899A (en) Acryronitrile-based compound, method for producing the same and pest controllingagent comprising the same
AU3855299A (en) Nanostructured film-type carbon material and method for producing the same
PL345537A1 (en) Plaster which contains steroids, and a method for the production and use thereof
AU9004598A (en) Ampule and method for manufacturing the same
AU2517999A (en) Self-supporting fusion-bonded film, method for producing said film and use of the same
HUP0002895A3 (en) 3-azabicyclo[3.1.0]hexanes, method for producing the same, and their use